CA
XBI icon

Cumberland Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Cumberland Advisors’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-170,790
Closed -$13.5M – 60
2022
Q3 		$13.5M Sell
170,790
-6,735
-4% -$568K 5.39% 6
2022
Q2 		$13.2M Sell
177,525
-138,790
-44% -$10.4M 4.38% 6
2022
Q1 		$28.4M Buy
316,315
+63,101
+25% +$5.83M 6.59% 3
2021
Q4 		$28.4M Sell
253,214
-4,100
-2% -$495K 5.94% 3
2021
Q3 		$32.3M Buy
257,314
+20,055
+8% +$2.58M 7.48% 2
2021
Q2 		$32.1M Buy
237,259
+66,018
+39% +$8.68M 7.54% 2
2021
Q1 		$23.2M Buy
171,241
+3,216
+2% +$482K 5.76% 3
2020
Q4 		$23.7M Buy
+168,025
New +$21.5M 8.66% 2
2020
Q2 		$13.5M Sell
120,269
-87,240
-42% -$8.59M 5.1% 6
2020
Q1 		$16.1M Sell
207,509
-645
-0.3% -$57.1K 6.55% 4
2019
Q4 		$19.8M Sell
208,154
-2,905
-1% -$251K 6.82% 4
2019
Q3 		$16.1M Buy
211,059
+5,230
+3% +$435K 4.55% 6
2019
Q2 		$18.1M Sell
205,829
-3,250
-2% -$277K 6.09% 5
2019
Q1 		$18.9M Buy
209,079
+23,660
+13% +$2.01M 6.56% 5
2018
Q4 		$13.3M Buy
185,419
+128,779
+227% +$10.4M 4.77% 7
2018
Q3 		$5.43M Buy
56,640
+13,420
+31% +$1.3M 3.63% 11
2018
Q2 		$4.11M Buy
43,220
+1,270
+3% +$117K 2.57% 18
2018
Q1 		$3.68M Buy
41,950
+290
+0.7% +$26.5K 2.25% 21
2017
Q4 		$3.54M Buy
41,660
+37,560
+916% +$3.15M 1.95% 23
2017
Q3 		$355K Sell
4,100
-60
-1% -$4.81K 0.22% 40
2017
Q2 		$321K Hold
4,160
– – 0.19% 42
2017
Q1 		$288K Sell
4,160
-1,300
-24% -$87.3K 0.18% 36
2016
Q4 		$323K Buy
+5,460
New +$337K 0.23% 35
2016
Q2 		– Sell
-38,160
Closed -$1.97M – 57
2016
Q1 		$1.97M Buy
+38,160
New +$1.98M 1.36% 20
2013
Q4 		– Sell
-77,970
Closed -$3.36M – 40
2013
Q3 		$3.36M Buy
77,970
+18,090
+30% +$733K 1.99% 15
2013
Q2 		$2.08M Buy
+59,880
New +$2.1M 1.14% 32

Other funds holding XBI

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Cumberland Advisors's XBI Position: Q4 2022 in Review

Cumberland Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2022, closing a stake of 170,790 shares — an estimated $13.5M sold.

Cumberland Advisors first reported a position in XBI in Q2 2013 and held it in 26 quarters. The position peaked at $32.3M in Q3 2021. 745 funds tracked by Wall St. Rank hold XBI as of Q4 2022.

  • Cumberland Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2022 after selling out during the quarter.
  • Cumberland Advisors sold 170,790 State Street SPDR S&P Biotech ETF shares in Q4 2022, an estimated $13.5M.
  • Cumberland Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and held it in 26 quarters.
  • Cumberland Advisors's State Street SPDR S&P Biotech ETF position peaked at $32.3M in Q3 2021.
  • 745 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2022.

Based on Cumberland Advisors's 13F filing for Q4 2022, filed 30 Jan 2023.